The European Commission has granted marketing authorization for Jemperli (dostarlimab) in combination with carboplatin-paclitaxel, for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.
Infinimmune and Grid Therapeutics formed a partnership to collaborate on identifying new antibody drug candidates for non-small cell lung cancer.
Elektrofi Inc., a biopharmaceutical formulation technology has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech Inc., a Johnson & Johnson company.
The National Cancer Institute approved the following clinical research studies last month.
To improve evidence generation in studies designed to bring therapeutic agents to market, FDA is urging drug sponsors not to skip dose optimization at the outset of clinical development. The agency is also telling industry that it’s open to accepting trials that have pragmatic elements and are augmented by data generated in academia.
The events of the past few weeks in Israel and Gaza, with all the tragic loss of life, are paralleled by another war—a war of words in the public arena reflecting political and ideological loyalties of those who are with, and those who are against.
Memorial Sloan Kettering Cancer Center received a $400 million gift from Kenneth C. Griffin, Citadel founder and CEO, and David Geffen, founder of the David Geffen Foundation.
University of Chicago Medicine received a $20 million gift from Susan and Tandean Rustandy to support development of Illinois’ first and only freestanding facility dedicated to cancer care and research, scheduled to open in 2027.
Pfizer Inc. has chosen to donate the rights of its royalties from the sale of Bavencio (avelumab) in the United States to the American Association for Cancer Research.
Julian Adams was named president and CEO of Stand Up To Cancer.
